Literature DB >> 3518774

Trends in the development of new medicines by UK-owned pharmaceutical companies (1964-1980).

R A Prentis, S R Walker.   

Abstract

One hundred and ninety-seven new chemical entities (NCEs) were investigated in man for the first time between 1964 and 1980 by the seven UK-owned pharmaceutical companies. Thirty-five of these NCEs have been marketed and 137 withdrawn from further research and development. There was an increase in the number of NCEs investigated each year, but this was counter-balanced by an increase in the number rejected. Development times increased from about 4.5 years in the 1960s to 9 years in the 1970s with an accompanying reduction in the effective patent life.

Entities:  

Mesh:

Year:  1986        PMID: 3518774      PMCID: PMC1400936          DOI: 10.1111/j.1365-2125.1986.tb05219.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  The development of self-originated new drugs by Swiss pharmaceutical firms, 1960-1980.

Authors:  N Mattison; E Thomas; A G Trimble; W M Wardell
Journal:  Regul Toxicol Pharmacol       Date:  1984-06       Impact factor: 3.271

2.  The rate of development of new drugs in the United States, 1963 through 1975.

Authors:  W M Wardell; M Hassar; S N Anavekar; L Lasagna
Journal:  Clin Pharmacol Ther       Date:  1978-08       Impact factor: 6.875

3.  A survey of products licensed in the United Kingdom from 1971-1981.

Authors:  J P Griffin; G E Diggle
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

4.  The measurement of pharmaceutical innovation.

Authors:  W M Wardell; J DiRaddo
Journal:  J Clin Pharmacol       Date:  1980-01       Impact factor: 3.126

5.  Drug innovation--what's slowing it down?

Authors:  F Steward; G Wibberley
Journal:  Nature       Date:  1980-03-13       Impact factor: 49.962

6.  Development of new drugs originated and acquired by United States-owned pharmaceutical firms, 1963-1976.

Authors:  W M Wardell; J DiRaddo; A G Trimble
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

  6 in total
  4 in total

Review 1.  Drug utilisation review and pharmacoeconomics: interaction after parallel development?

Authors:  S Garattini; G Tognoni
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

2.  Novel medicines marketed in the UK (1960-87).

Authors:  Y Lis; S R Walker
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

3.  Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).

Authors:  R A Prentis; Y Lis; S R Walker
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

4.  Animal to human translation: a systematic scoping review of reported concordance rates.

Authors:  Cathalijn H C Leenaars; Carien Kouwenaar; Frans R Stafleu; André Bleich; Merel Ritskes-Hoitinga; Rob B M De Vries; Franck L B Meijboom
Journal:  J Transl Med       Date:  2019-07-15       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.